Currently attending the discussion held by the @CPSolvers Anti-Racism in Medicine team on moving moving towards anti-racism in medical education. Right now @UREssien is describing the ways in which racism is ingrained in medical education and medicine as a whole. #SGIM21
Examples: over-emphasis on biological constructions of race/biological predictors of health disparities.
.@rohankhaz noted the importance of med learners engaging, honoring and becoming educated on a community's history with respect to racism, segregation, and patients' lived experiences.
.@NaomiFFields When given the opportunity, people (e.g. students/trainees) who may not have experience with anti-racist concepts are willing and able to learn.
.@jazzminciara We can't just limit education on racism in medicine to a three-week course, must be integrated into systems-based curriculum, and beyond.
.@jazzminciara makes the excellent point that the burden of educating people + institutions on anti-racism is often on students of color. Leadership/institutions can relieve that burden by identifying ways to compensate students/informal educators for their time eg LORs, titles.
.@DrChelleMD on allyship--must go beyond being an ally to being a 'co-conspirator'; "putting down your privilege and handing it to someone else" is difficult but critical to anti-racist work.
.@UREssien "For all the folks wondering if they should go into medicine, we need you. [...] We are seeing the tide shift towards addressing anti-racism in medical education."
• • •
Missing some Tweet in this thread? You can try to
force a refresh
Currently watching the pre-recorded Update in Primary Care which reviews the 10 most impactful articles published in @AnnalsofIM, @NEJM, @TheLancet, ACP Journal Club, @JAMA_current, and @JAMAInternalMed from the past 2 years, as selected by a panel of SGIM physicians. #SGIM21
Study 1: 'Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction" by J.J. V. McMurray, et al. @NEJM pub. date Nov 21, 2019; nejm.org/doi/full/10.10… DAPA-HF trial bottom line: in pts with HFrEF, regardless of diabetes, dapagliflozin reduced HF and CV death.
Study 2: 'Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer' by Giancarlo Angelli, et al. @NEJM pub date March 29 2020 nejm.org/doi/full/10.10… Bottom line: in pts w/ cancer-associated VTE, apixaban is not inferior to dalteparin for preventing recurrence.
Currently attending the plenary PLN3: Realizing True Health Equity- An Equal Opportunity To Be Healthy For All. #SGIM21 Right now @daynamatthew3 is discussing the historical + constitutional foundation of racism and inequality in the U.S., and its impact on health outcomes today.
.@daynamatthew3 "If you want to translate values into action as a physician, I implore you to consider your role in using law as one of your weapons of choice." Cites 1963 Simkins v. Cone federal lawsuit to desegregate hospitals.
.@daynamatthew3: Disparate rates of COVID-19 among communities of color is not due to vaccine hesitancy or lack of trust. Uses example of plane crash survivors who were seated at the front vs. wings of the planes--"where you sit on the plane determines your life chances."